626 / 1068
IMRT & GI toxicity
- But….negative report from a controlled trial
- NRG Oncology RTOG0822 study (IMRT to decrease acute GI tox 45Gy +
boost 5.4Gy concomitant with Capecitabine/Oxaliplatin)
- Sampled to detect ≥12% reduction of acute grade 2-5 CTC_AEv.3.0
compared to RTOG0247
- Rate 51 % vs 40% (RTOG0247) vs 28% (provisional)
- Rate grade 3 diarrhea similar to studies using 3DCRT
Hong 2015